Armed with positive results from two studies, Roche is one step closer to entering the MS market. And when it does, other players in the field had better watch out, analysts say: Formulary pressure will be ramping up.
Roche heralded the late-stage success of two big trials for its multiple sclerosis drug ocrelizumab today, which they say puts them on a straight road to regulatory filings for the injectable in early 2016. But even under the best-case scenario for the future, the Big Pharma player will face a tough task squaring off against the new oral drugs that have been divvying up this big market recently.
Ablynx has entered into a collaboration with Sanofi's Genzyme to investigate the use of its single-domain antibodies against a target involved with multiple sclerosis. The deal gives Genzyme the exclusive right to test the antibodies in models relevant to multiple sclerosis.
A research team at the University of Montreal has come up with some preclinical data to support a development program--now underway at the Irish biotech Prothena--which is targeting a new approach for halting the progression of multiple sclerosis.
Biogen's latest treatment for multiple sclerosis helped repair damaged nerve tissue in a Phase II study, an incremental victory for a novel therapy that has a long way to go.
Biogen's latest evolution is more than just a nominal shift, according to its CEO, as the Big Biotech lops the Idec from its name and hopes to parlay its success in multiple sclerosis into some tough-to-treat diseases.
A group of investigators at the University of Chicago says they've found a drug that can guard myelin-producing cells, offering a possible new route to guarding against multiple sclerosis. And this is one therapy that has already been through the approval process.
Testing a theory that the molecule that transports proteins from the nucleus of a cell to the cytoplasm is altered in neurodegenerative diseases like multiple sclerosis, investigators say that they have successfully completed an animal study that tested drugs that could block the molecule and perhaps repair nerve cell damage that occurs in MS.
The former head of Johnson & Johnson's initiative to develop stratified drugs for Alzheimer's disease is trying to crowdfund the development of computer simulations of brain disorders. Magali Haas is seeking $299,900 for the project, which builds on a multiple sclerosis prediction model created by her nonprofit, Orion Bionetworks.
Alkermes said the safety profile of its clinical-stage multiple sclerosis drug compares favorably to that of Biogen Idec's Tecfidera, citing the candidate's Phase I trial results on 104 patients.